Method of managing or treating pain
View Patent ↗A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (C max ) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.
1. A method of treating or managing pain by intranasally administering to an animal in need thereof in a single dosage regimen having a practical dose volume to provide rapid absorption in combination with a lower peak plasma concentration than that provided using a simple aqueous solution and in an amount to effectively treat or manage pain, a pharmaceutical composition comprising an aqueous solution of
fentanyl or a pharmaceutically acceptable salt thereof in an amount to effectively treat or manage pain that is from 0.1 to 30 mg/ml of fentanyl or a pharmaceutically acceptable salt thereof (expressed as fentanyl base) and
a pectin having a degree of esterification (DE value) of less than 30%, provided that the composition is substantially free of divalent metal ions;
wherein the animal administered the composition in the single dosage regimen is provided with a peak plasma concentration of fentanyl (C max ) that is from 20 to 75% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose; and
wherein the intranasal administration of the composition provides a time to achieve peak plasma concentration (T max ) of fentanyl in the animal's plasma of 5 to 30 minutes.
2. A method according to claim 1 , wherein the animal administered the composition by the single dosage regimen is provided with a peak plasma concentration of fentanyl (C max ) that is from 30 to 70% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose.
3. A method according to claim 1 , wherein the pectin has a DE value of from 7 to 30%.
4. A method according to claim 3 , wherein the pectin has a DE value of from 10 to 25%.
5. A method according to claim 1 , wherein the pectin has a DE value of from 5 to 25%.
6. A method according to claim 1 , wherein the animal administered the composition by the single dosage regimen is provided with a peak plasma concentration of fentanyl (C max ) that is from 30 to 70% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose, and wherein the pectin has a DE value of from 5 to 25%.
7. A method according to claim 1 , wherein the composition comprises a pharmaceutically acceptable salt of fentanyl.
8. A method according to claim 7 , wherein the pharmaceutically acceptable salt of fentanyl is fentanyl citrate.
9. A method according to claim 1 , wherein the composition has a concentration of pectin from 5 to 25 mg/ml of the composition.
10. A method according to claim 1 , wherein the composition is at least 99% free of divalent metal ions.
11. A method according to claim 1 , wherein the composition has an osmolality of from 0.25 to 0.35 osmol/kg.
12. A method according to claim 1 , wherein the composition has a pH of from 3.4 to 5.0.
13. A method according to claim 1 , wherein the composition is administered by the single dosage regimen in the form of drops or as a spray.
14. A method according to claim 1 for treating acute or chronic pain.
15. A method according to claim 1 , wherein the animal is a human.
16. A method according to claim 1 , wherein the composition comprises from 0.1 to 20 mg/ml of the composition of fentanyl or a pharmaceutically acceptable salt thereof (expressed as fentanyl base).
17. A method according to claim 16 , wherein the composition comprises from 0.2 to 16 mg/ml of the composition of fentanyl or a pharmaceutically acceptable salt thereof (expressed as fentanyl base) of the composition.
18. A method of treating or managing pain by intranasally administering to an animal in need thereof in a single dosage regimen having a practical dose volume to provide rapid absorption in combination with a lower peak plasma concentration than that provided using a simple aqueous solution and in an amount to effectively treat or manage pain, a pharmaceutical composition comprising an aqueous solution of
0.2 to 16 mg/ml (expressed as fentanyl base) of fentanyl or a pharmaceutically acceptable salt thereof and
5 to 25 mg/ml of a pectin having a DE value of 10 to 25%;
the composition having a pH of 3.4 to 5.0 and an osmolality of 0.2 to 0.4 osmol/kg and being substantially free of divalent metal ions;
so as to provide in the animal administered the composition a peak plasma concentration of fentanyl (C max ) that is from 20 to 75% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose and a time to achieve peak plasma concentration (T max ), of fentanyl in the animal's plasma of 5 to 30 minutes.
19. A method according to claim 18 , wherein the animal is a human.
20. A method according to claim 19 , wherein the single dosage regimen of the method further comprises administering the composition to the human via a maximum of two intranasal sprays to each nostril of the human where the maximum volume of each spray is 0.15 ml of the composition.
21. A method according to claim 15 , wherein the single dosage regimen of the method further comprises administering the composition to the human via a maximum of two intranasal sprays to each nostril of the human where the maximum volume of each spray is 0.15 ml of the composition.
22. A method of treating or managing pain by intranasally administering to an animal in need thereof in a single dosage regimen having a practical dose volume to provide rapid absorption in combination with a lower peak plasma concentration than that provided using a simple aqueous solution and in an amount to effectively treat or manage pain, a pharmaceutical composition comprising an aqueous solution of
fentanyl or a pharmaceutically acceptable salt thereof in an amount to effectively treat or manage pain that is from 0.1 to 30 mg/ml of fentanyl or a pharmaceutically acceptable salt thereof (expressed as fentanyl base);
a pectin having a degree of esterification (DE value) of less than 30%; and
a non-metal ion osmolality adjusting agent in an amount to ensure that the osmolality of the composition is from 0.2 to 0.8 osmol/kg;
provided that the composition is substantially free of divalent metal ions;
wherein the animal administered the composition is provided with a peak plasma concentration of fentanyl (C max ) that is from 20 to 75% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose; and
wherein the intranasal administration of the composition provides a time to achieve peak plasma concentration (T max ) of fentanyl in the animal's plasma of 5 to 30 minutes.
23. The method of claim 22 , wherein the non-metal ion osmolality adjusting agent is selected from one or more in the group consisting of mannitol, sorbitol, dextrose, sucrose and trehalose.
24. The method of claim 22 , wherein the osmolality of the composition is from 0.2 to 0.4 osmol/kg.
25. The method of claim 24 , wherein the osmolality of the composition is from 0.25 to 0.35 osmol/kg.
26. The method of claim 18 , wherein the osmolality of the composition is from 0.25 to 0.35 osmol/kg.